Fairmont Banff Springs Floorplan
This meeting took place in 2023
Here are the related meetings in 2024:
Antibodies as Drugs: The Art in Antibody Engineering (C6)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Next Generation Antibody Therapeutics: From Discovery to Patient (Q5)
Organizer(s) Pamela M. Holland and James A. Wells
February 19—22, 2023
Fairmont Banff Springs • Banff, AB Canada
Abstract Deadline: Nov 28, 2022
Scholarship Deadline: Nov 28, 2022
Discounted Registration Deadline: Dec 15, 2022
Sponsored by Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Genmab A/S, GlaxoSmithKline Biologicals and Surface Oncology
Summary of Meeting:
Therapeutic antibodies have become the predominant class of new drugs gaining FDA and have positively impacted the most patients for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, MOA, protein design, development time, and managing increasing costs of antibody manufacturing. The aim of this conference will be to provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Specifically, this conference will focus on 1) target identification and novel discovery platforms, 2) advances in protein engineering to improve functional properties and new antibody modalities and delivery methods and 3) an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. We envision this program will offer investigators an overview of antibody therapy development from bench to bedside and also highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists.
View Scholarships/Awards
Therapeutic antibodies have become the predominant class of new drugs gaining FDA and have positively impacted the most patients for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, MOA, protein design, development time, and managing increasing costs of antibody manufacturing. The aim of this conference will be to provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Specifically, this conference will focus on 1) target identification and novel discovery platforms, 2) advances in protein engineering to improve functional properties and new antibody modalities and delivery methods and 3) an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. We envision this program will offer investigators an overview of antibody therapy development from bench to bedside and also highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, February 23 in order to fully experience the meeting.
SUNDAY, FEBRUARY 19
MONDAY, FEBRUARY 20
TUESDAY, FEBRUARY 21
WEDNESDAY, FEBRUARY 22
THURSDAY, FEBRUARY 23
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, February 23 in order to fully experience the meeting.
SUNDAY, FEBRUARY 19
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address (Joint)
*
Pamela M. Holland,
InduPro, USA
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
*
James A. Wells,
University of California, San Francisco, USA
Tomoyuki Igawa,
Chugai Pharmaceutical, Japan
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment
09:00—11:15
Conditional Targeting with Multi-Specific Engagers (Joint)
*
Pamela M. Holland,
InduPro, USA
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
Katarina Pance,
Epi Biologics, USA
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins
Coffee Break
Wendy Ritacco,
AbbVie Bioresearch Center, USA
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models
Edward van der Horst,
Sensei Biotherapeutics, USA
Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics
Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics
14:30—16:30
Workshop 1: New Ab Therapeutics and Engineering Platforms
Yanay Ofran,
Biolojic, Israel
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs
Maxwell Stefan,
Twist Biosciences, USA
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library
Nazanin Larijani,
National Research Council, Canada
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas
Frank J. Beurskens,
Genmab, Netherlands
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens
Adam Zwolak,
Janssen R&D, USA
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor
*
Christoph Rader,
The Scripps Research Institute, USA
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution
Malin Jönsson,
KTH Royal Institute of Technology, Sweden
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential
Lorenzo Maso,
NYULMC, USA
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy
17:00—19:00
Antibody Modality
Shelley Ackerman,
Bolt Biotherapeutics, USA
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity
*
John R. Desjarlais,
Xencor, Inc., USA
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3
Sai T. Reddy,
ETH Zurich, Switzerland
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity
Francisco Leon,
Provention Bio, Inc, USA
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders
17:00—19:00
Immune Synapse and Design of Immune Cell Engagers
Michael L. Dustin,
University of Oxford, UK
Molecular Insights into the Immune Cell Synapse Relevant to Immune Cell Engagers
Molecular Insights into the Immune Cell Synapse Relevant to Immune Cell Engagers
Rebecca Chen,
Pfizer, Inc., USA
One Size Does Not Fit All: Navigating the Multi-dimensional Space to Optimize T-cell Engaging Bispecific Antibodies
One Size Does Not Fit All: Navigating the Multi-dimensional Space to Optimize T-cell Engaging Bispecific Antibodies
*
Daniel S. Chen,
Engenuity Life Sciences, USA
Multimeric Engagers: Cytotoxicity, Cytokine Release and the T cell Power Curve
Multimeric Engagers: Cytotoxicity, Cytokine Release and the T cell Power Curve
Matthew I. J. Raybould,
University of Oxford, UK
Short Talk: Computationally Profiling Peptide:MHC Recognition by T-cell Receptors and T-Cell Receptor-mimetic Antibodies
Short Talk: Computationally Profiling Peptide:MHC Recognition by T-cell Receptors and T-Cell Receptor-mimetic Antibodies
Raffi Tonikian,
AbCellera, Canada
Short Talk: Streamlining T-cell Engager Development with a Diverse Panel of Fully Human CD3-binding Antibodies, Bispecific Engineering Technology, and an Integrated Discovery Engine
Short Talk: Streamlining T-cell Engager Development with a Diverse Panel of Fully Human CD3-binding Antibodies, Bispecific Engineering Technology, and an Integrated Discovery Engine
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
New Approaches Toward Target Identification
*
Bernd Wollscheid,
ETH Zürich, Switzerland
Leveraging Surfaceome Nanoscale Organization for Theranostics
Leveraging Surfaceome Nanoscale Organization for Theranostics
James A. Wells,
University of California, San Francisco, USA
Cell Surface Protolysis for Neo-Epitopes
Cell Surface Protolysis for Neo-Epitopes
Coffee Break
Niyi Fadeyi,
InduPro, USA
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface
Erica Ollmann Saphire,
La Jolla Institute for Immunology, USA
Structural Biology of Viruses Toward Therapeutic Development
Structural Biology of Viruses Toward Therapeutic Development
Garrett Rappazzo,
Adimab LLC, USA
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform
08:00—11:00
Resistance Mechanisms to Immune Cell Engagers
Marion Subklewe,
LMU University Hospital Munich, Germany
Adaptive Immune Resistance and Checkpoint Inhibiting Trispecific Engagers
Adaptive Immune Resistance and Checkpoint Inhibiting Trispecific Engagers
*
Joaquín Arribas,
Vall d'Hebron Institute of Oncology, Spain
IFN-Signaling and Acquired Cancer Cell Resistance to T Cell Engagers
IFN-Signaling and Acquired Cancer Cell Resistance to T Cell Engagers
Coffee Break
Katherine Beglinger,
Merck & Co., Inc., USA
Engineering a Trispecific T-cell Receptor Engager (TREy) with Increased Potency and Selectivity for Tumor Immunotherapy
Engineering a Trispecific T-cell Receptor Engager (TREy) with Increased Potency and Selectivity for Tumor Immunotherapy
Christopher E. Rudd,
University of Montreal, Canada
Immune Adaptor SLP-76 Regulates Metabolic and Killing CD8+ T Cells Responses against Tumors
Immune Adaptor SLP-76 Regulates Metabolic and Killing CD8+ T Cells Responses against Tumors
14:30—16:00
Workshop 2: Emerging Approaches to Expand Biologic Therapies
Benjamin Bell,
Merck & Co., Inc., USA
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics
*
Andrea Imle,
BioNTech SE, Germany
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking
Jonathan Back,
GlycoEra, Switzerland
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders
Noel T. Pauli,
Adimab LLC, USA
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform
Shaheen Farhadi,
Merck & Co., Inc., USA
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies
17:00—19:00
Emerging Costimulatory Therapies in Oncology (Joint)
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations
Janelle Christine Waite,
Regeneron, USA
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies
*
Pamela M. Holland,
InduPro, USA
Conditional Targeting of CD28 in the Tumor Micorenvironment
Conditional Targeting of CD28 in the Tumor Micorenvironment
Sara Majocchi,
Novimmune SA, Switzerland
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Discovery Platforms
*
Jamie Spangler,
Johns Hopkins University, USA
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery
Shohei Koide,
New York University Langone Health, USA
Targeting Intracellular Proteins with Biologics
Targeting Intracellular Proteins with Biologics
Coffee Break
Mart Ustav Jr.,
Icosagen Cell Factory OÜ, Estonia
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells
Nora Karnowski,
Apis Assay Technologies Ltd, Germany
Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers
Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers
Bhuvaneshwari Shunmuganathan,
National university of singapore, Singapore
Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19
Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19
08:00—11:00
Enhancing Immune Engager Safety and Efficacy: Alternative Combination Strategies
*
Marion Subklewe,
LMU University Hospital Munich, Germany
Teemu T. Junttila,
Genentech, Inc., USA
Understanding and Addressing Cytokine Release Syndrome from T Cell Engagers
Understanding and Addressing Cytokine Release Syndrome from T Cell Engagers
Junyun Lai,
Peter MacCallum Cancer Centre, Australia
Stimulating Dendritic Cells to Enhance Epitope Spreading from Synthetic T Cell Redirection
Stimulating Dendritic Cells to Enhance Epitope Spreading from Synthetic T Cell Redirection
Coffee Break
Nadine van Montfoort,
Leiden University Medical Center, Netherlands
Preconditioning the Immune Microenvironment of Excluded Tumors for Bispecific T-Cell Engagers
Preconditioning the Immune Microenvironment of Excluded Tumors for Bispecific T-Cell Engagers
Nora Philipp,
LMU University Hospital Munich, Germany
Short Talk: Bispecific´s Best Buddies: Combinatorial Treatment Strategies to Mitigate T-Cell Exhaustion
Short Talk: Bispecific´s Best Buddies: Combinatorial Treatment Strategies to Mitigate T-Cell Exhaustion
Mohosin Sarkar,
Evolveimmune Therapeutics, USA
Short Talk: EVOLVE: A Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Immune Suppressive Solid and Hematologic Cancers
Short Talk: EVOLVE: A Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Immune Suppressive Solid and Hematologic Cancers
Carston R. Wagner,
University of Minnesota, USA
Short Talk: Eradication Of Heterogeneous Tumors By T-Cells Targeted with Combination Bispecific Chemically Self-Assembled Nanorings (CSANs)
Short Talk: Eradication Of Heterogeneous Tumors By T-Cells Targeted with Combination Bispecific Chemically Self-Assembled Nanorings (CSANs)
Edward Seung,
ModeX Therapeutics, USA
Short Talk: A Trispecific Antibody Targeting HER2 and T Cells Inhibits Breast Cancer Growth via CD4 Cells
Short Talk: A Trispecific Antibody Targeting HER2 and T Cells Inhibits Breast Cancer Growth via CD4 Cells
15:00—16:30
Career Roundtable (Joint)
Markus G. Manz,
University Hospital Zürich, Switzerland
Francisco Leon,
Provention Bio, Inc, USA
Jamie Spangler,
Johns Hopkins University, USA
17:00—18:45
Emerging Antibody Therapeutics in Infectious Disease
*
James A. Wells,
University of California, San Francisco, USA
Christopher O. Barnes,
Stanford University, USA
Structural Characterization of Antibody Responses to SARS-CoV-2
Structural Characterization of Antibody Responses to SARS-CoV-2
Ting Y. Wong,
WRAIR, USA
Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis
Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis
Elizabeth Parzych,
Wistar Institute, USA
Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2
Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2
Jason Kang,
West Virginia University, USA
Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection
Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection
17:00—18:45
Innate Immune Cell Engagers
*
Markus G. Manz,
University Hospital Zürich, Switzerland
Marjolein van Egmond,
VU University Medical Center, Netherlands
Bispecific Neutrophil Engagers for Cancer Immunotherapy
Bispecific Neutrophil Engagers for Cancer Immunotherapy
Yannis Morel,
Innate Pharma, France
Trispecific NK Cell Engagers
Trispecific NK Cell Engagers
Christine Trumpfheller,
Roche Glycart, Switzerland
Targeted Myeloid Cell Engagement via Bispecific CD40 Agonists
Targeted Myeloid Cell Engagement via Bispecific CD40 Agonists
Hans van der Vliet,
Lava Therapeutics, Netherlands
GammaDelta T-Cell Bispecific Engagers
GammaDelta T-Cell Bispecific Engagers
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
We gratefully acknowledge additional support from these exhibitors at this conference:
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
Nicoya Lifesciences |
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |